LUNG
Pulmonx Corporation Common Stock
stockNASDAQ
pulmonx is focused on developing life-changing technologies that improve the lives of patients suffering from lung disease. the company's first commercial products address emphysema, a form of copd (chronic obstructive pulmonary disease) and the largest unmet medical need in pulmonology. with emphysema, breathing becomes increasingly more difficult as the disease progresses. today in the u.s., advanced emphysema patients have no available alternatives but lung volume reduction surgery, which is associated with high morbidity and mortality, and lung transplantation, which is limited by the availability of donor organs. pulmonx has developed the zephyr endobronchial valve (ebv) therapy, a non-surgical, investigational approach to treating emphysema. the minimally invasive zephyr valve is a tiny, one-way valve designed to reduce the volume of the diseased regions of the lung by blocking airflow, in order to improve breathing and increase activity levels. no surgery is involved in the simp
| Period | Price | Date | Change | Beta |
|---|---|---|---|---|
| 1W | 1.83 | 2026-10-21 | +42.08% | 1.872 |
| 1M | 1.96 | 2026-09-28 | +32.65% | 0.799 |
| 3M | 1.25 | 2026-07-28 | +108.00% | 3.067 |
| 6M | 1.23 | 2026-04-28 | +111.38% | 2.276 |
| 1Y | 1.98 | 2025-10-28 | +31.31% | 1.986 |
| 2Y | 6.21 | 2024-10-28 | -58.13% | — |
| 5Y | 39.65 | 2021-10-28 | -93.44% | 1.397 |
Pulmonx Corporation Common Stock (NASDAQ:LUNG) stock price today is $2.60, and today's volume is 5,203,262. LUNG is up 31.313% today. The 30 day average volume is 286,798. LUNG market cap is $111.67M with 42.95M shares outstanding.